Skip to content

Strong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists

Julian D Sandbrink, Kyle Johnson, Maureen Gill, David B Yaden, Julian Savulescu, Ivar R Hannikainen, Brian D Earp

AJOB Neuroscience February 5, 2024 DOI: 10.1080/21507740.2024.2303154 via OpenAlex

Summary

AI-generated from the abstract

A nationally representative sample of 795 US Americans rated the moral status of psilocybin use in a licensed setting as morally positive for both treating a psychiatric condition and enhancing well-being, showing strong bipartisan support. These attitudes can inform policy-making around supervised psilocybin use. The study did not explore attitudes toward unsupervised or non-licensed use.

Study at a glance

Characteristics Cross-sectional survey Peer reviewed
Sample size 795
Population Nationally representative sample of US Americans
Topics Psilocybin
Keywords Governance Enhancement Mental health Treatment Psychedelics hallucinogens
Citations 13
Key finding Participants rated psilocybin use in a licensed setting as morally positive for both treatment and well-being enhancement, with strong bipartisan support.

Abstract

The psychedelic psilocybin has shown promise both as treatment for psychiatric conditions and as a means of improving well-being in healthy individuals. In some jurisdictions (e.g., Oregon, USA), psilocybin use for both purposes is or will soon be allowed and yet, public attitudes toward this shift are understudied. We asked a nationally representative sample of 795 US Americans to evaluate the moral status of psilocybin use in an appropriately licensed setting for either treatment of a psychiatric condition or well-being enhancement. Showing strong bipartisan support, participants rated the individual's decision as morally positive in both contexts. These results can inform effective policy-making decisions around supervised psilocybin use, given robust public attitudes as elicited in the context of an innovative regulatory model. We did not explore attitudes to psilocybin use in unsupervised or non-licensed community or social settings.

Explore topics

Comments

No comments yet.

Log in to comment